Welcome to our dedicated page for STEPAN CO SEC filings (Ticker: SCL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Stepan Company filings document the regulatory record for a specialty and intermediate chemicals manufacturer whose common stock trades on the New York Stock Exchange under symbol SCL. Its 8-K filings report operating results, dividend declarations, material-event disclosures, capital-structure information and exit or disposal activities tied to manufacturing and efficiency initiatives.
Stepan proxy and annual-meeting filings cover director elections, advisory compensation votes, auditor ratification, executive compensation governance and benefit-plan matters. The filing record also includes disclosure on restructuring charges, asset write-downs, decommissioning costs and other governance or financial matters reported through current reports and proxy materials.
Stepan Company executive Sean Thomas Moriarty, VP & GM Surfactants, reported multiple equity awards. On March 2, 2026, he was granted 7,155 Stock Appreciation Rights that vest ratably over three years, 4,495 Restricted Stock Units, and 2,247 performance shares, each representing a contingent right to one share of Stepan common stock.
The performance shares vest upon certification that Stepan achieved specified performance goals for the period ending December 31, 2028. On February 27, 2026, he also acquired 56.765 shares of common stock at $52.5100 per share. The filing notes an additional 4,478.3510 common shares held indirectly through an ESOP II Trust.
STEPAN CO reported that executive Richard Finn Stepan, Vice President and General Manager, Polymers, received several equity incentives. On March 2, 2026, he was granted 7,155 stock appreciation rights that vest ratably over three years, beginning on that date.
He also acquired 2,497 performance shares and 4,994 restricted stock units, each representing a contingent right to receive one share of Stepan common stock. The performance shares vest when the company certifies that performance goals for the period ending December 31, 2028 are achieved, while the RSUs vest ratably over three years from the grant date.
On February 27, 2026, he was awarded 56.765 shares of common stock at $52.51 per share. The filing also lists indirect common stock holdings attributed to his daughter, son, spouse, a trust, and an ESOP II trust, reflecting additional ownership positions reported as indirect.
STEPAN CO reported new equity awards granted to Vice President and Chief Financial Officer Ruben Dario Velasquez. On February 27, 2026, he acquired 35.601 shares of common stock at $52.51 per share as an award. On March 2, 2026, he received grants of 5,993 restricted stock units, 2,996 performance shares, and 8,586 stock appreciation rights, all recorded at a price of $0. Each restricted stock unit and performance share represents a contingent right to receive one share of common stock, with the restricted stock units vesting ratably over three years and the performance shares vesting based on performance goals for a period ending December 31, 2028.
Stepan Co President & CEO Luis Rojo reported equity awards that increase his stake in the company. On March 2, 2026, he received 19,976 Restricted Stock Units, 39,952 performance shares, and a Stock Appreciation Right covering 57,241 shares, all at a stated price of $0.00 per unit.
Each RSU and performance share represents a contingent right to receive one share of Stepan common stock, with RSUs vesting in equal installments over three years and performance shares vesting after certification of performance for the period ending December 31, 2028. On February 27, 2026, he also acquired 56.765 shares of common stock at $52.51 per share, bringing his directly held common stock to 15,697.666 shares, plus 511.83 shares held indirectly through an ESOP II trust.
Stepan Company files its annual report describing a global specialty and intermediate chemicals business organized into Surfactants, Polymers and Specialty Products. It sells mainly to manufacturers rather than directly to consumers, serving cleaning, personal care, construction, agriculture, oilfield and food/pharma markets.
The company highlights environmental and regulatory compliance, spending $9.8 million on related capital projects and $44.9 million on recurring environmental operating costs in 2025. It launched Project Catalyst in February 2026, targeting about $100 million in pre-tax savings over two years through operational and efficiency initiatives.
Management discusses key risks, including hazardous chemical operations, raw material and energy volatility, transportation disruptions, geopolitical tensions, evolving chemical and product regulations, cybersecurity threats and legal liabilities. Stepan also notes significant indebtedness, with long-term notes and a revolving credit facility, and emphasizes strong safety culture, human capital development and a formal enterprise risk management and cybersecurity governance framework.
Stepan Company announced Project Catalyst, a comprehensive operational and efficiency plan targeting approximately $100 million in pre-tax savings over the next two years. To achieve this, the company will close its Fieldsboro, New Jersey site and decommission select assets at its Elwood (Millsdale), Illinois and Stalybridge, United Kingdom facilities by mid-2026, consolidating production into its existing network.
Stepan expects restructuring charges of $70–$80 million in 2026, with about $52–$62 million recognized in the first quarter of 2026. Over the life of the project, cash impacts are projected at $29–$44 million and non-cash impacts at $58–$62 million, primarily related to asset write-downs, decommissioning costs and related expenses.
Stepan Company reported solid full-year 2025 growth with signs of near-term pressure. Net sales rose to $2.33 billion, up 7%, while reported net income declined to $46.9 million, down 7%, as higher interest expense, a less favorable tax rate and a $6.2 million goodwill impairment weighed on results.
Adjusted net income fell 17% to $41.7 million, but adjusted EBITDA increased 6% to $198.9 million, showing better underlying cash earnings. Surfactants grew revenue yet saw lower earnings, while Polymers and Specialty Products delivered higher operating income. Free cash flow of $25.4 million in the fourth quarter helped cut net debt and reduce the net debt ratio to 28%.
The company launched Project Catalyst, targeting about $100 million in pre-tax savings over the next two years through a portfolio and footprint reset, including closing its Fieldsboro, New Jersey site and decommissioning assets at Millsdale, Illinois and Stalybridge, UK. Stepan also declared a quarterly dividend of $0.395 per share, payable March 13, 2026, extending its 58-year streak of dividend increases.
STEPAN CO President & CEO Luis Rojo reported equity award activity involving restricted stock units and common shares. On the reported date, 683 restricted stock units were exercised and settled into 683 shares of common stock at $66.3900 per share. To cover tax obligations, 237 common shares were disposed of through a tax-withholding transaction, leaving 15,640.901 common shares held directly after these transactions. An additional 511.8300 common shares are held indirectly through the Esop II Trust. The filing also amends a prior report to correct the dates for “Date Exercisable” and “Expiration Date” on the related award.
STEPAN CO executive Richard Finn, Vice President and General Manager of Polymers, reported equity award activity in company stock. On February 17, 2026, 341 restricted stock units were exercised and settled into 341 shares of common stock at $66.39 per share, consistent with the award terms.
To cover taxes on the RSU vesting, 118 shares of common stock were withheld, also at $66.39 per share. After these transactions, Finn directly held 241,339.15 shares of common stock. He also reported indirect holdings, including 43,439 shares held by a daughter, 5,174 by a spouse, 95,416 by a trust, and 1,238.22 by an ESOP II trust.
Stepan Company executive Sean Thomas Moriarty reported equity award activity involving restricted stock units and common stock. On February 17, 2026, 455 restricted stock units were exercised into 455 shares of Stepan common stock at a stated price of $66.39 per share, consistent with an exercise or conversion of derivative securities. To cover tax obligations on the RSU vesting, 158 common shares were disposed of through share withholding, rather than an open-market sale. After these transactions, Moriarty directly holds 14,145.4635 shares of Stepan common stock and indirectly holds 4,478.3510 shares through the ESOP II Trust.